This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Pharma And Payers - Building Better Relationships

NEW YORK, Oct. 30, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharma and Payers – Building Better Relationships http://www.reportlinker.com/p01021205/Pharma-and-Payers-–-Building-Better-Relationships.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Changes in the healthcare landscape have put payers (public and private) under mounting pressure to reduce the cost of care, and given them much greater influence over market access to new medicines.

In this new environment, regulatory approval of new drugs no longer guarantees favourable pricing and formulary placement. Instead, payers focus increasingly on value to determine pricing and access.

Drug developers need to understand the value review process, and adapt their organisation to engaging payers early in the journey. More profoundly, pharma companies must find ways to evolve their current transactional, and even adversarial, relationships with payers to more collaborative ones. After all, Pharma and payers share the same ultimate goals – to lower costs and improve care.

This new report helps Pharma and payers build a "win-win" relationship; by understanding each other's needs, and by exploring new opportunities for collaboration.

Report Overview This extensive report includes a wealth of information and tools that empower Pharma and payers to work together more effectively, with the ultimate goal of offering patients access to life-saving drugs, biologics, and vaccines.

After painting a detailed picture of the current environment (including explaining regional payer systems, and key factors driving change), the report offers a fascinating exploration of "what payers want". You'll learn about the primary ways in which payers are measuring outcomes (e.g., QALY, CER, pragmatic clinical trials), and discover best practices in resource allocation, organisation, communication, and accountability.

The report includes real case studies of successful pharma-payer partnerships (such as risk-sharing agreements, clinical outcomes studies), and draws on expert opinions and advice from more than a dozen of the world's foremost thought leaders and executives in this space.

Key Report Features Detailed insights into what payers want from Pharma (and vice versa) Recent case studies of collaborations between major pharma companies and payers Practical advice on meeting payers' needs and tackling potential problems Review of the growing influence of patients/consumers Description of different types of payers Guide to the payer frameworks in key markets (US, UK, and the leading European pharma markets: Germany, France)

Key Benefits

Learn from successful collaborations between payers and Pharma Understand what payers expect and want from Pharma Improve Pharma-payer communications Optimise your organisational structure to meet payer needs Be aware of potential pitfalls Generate successful drug pricing and formulary placement discussions Be ready for future developments

Who Should Read This Report?

Pharma executives in Market Access, Pricing, Reimbursement, Strategic Planning, and Marketing Payer executives and representatives, including health insurance providers, government payers, pharmacists, social security, and local health authorities Executives in Clinical Development Health Economics and Outcomes Research leaders

Key Questions Answered

What kinds of data (e.g., around safety and efficacy) are most useful for improving market access? What are the key differences and common denominators between the payers in the US and key European markets? Who are the best people to represent Pharma in payer negotiations? At what stage of drug development should the payers, or pricing and reimbursement consultants, become involved? What kind of risk-sharing arrangements can be made between pharma and payers? What opportunities are there for win-win collaborations?

Expert Views Include:

Steve Phillips, director, Health Policy and Reimbursement, Johnson and Johnson — government health policy leader and advisor to all J&J operating companies Tehseen Salimi, vice president, Customer Medical Synergies, Sanofi-Aventis — payer interaction leader, scheduled to speak at Evidence Based Reimbursement Summit 2012 Dr. Marcus Wilson, vice president, WellPoint, HealthCore Inc — pioneer in real-world outcomes research Terri Bernacchi, managed care pharmacist/consultant, engaged with several US health plans and IMS Health Managed Market Services — expert and author on payer engagement Michael Hurwich, president, Strategic Pricing Management Group — one of the world's foremost pricing, revenue & strategy management consultants Cyndy Nayer, president and founder, Center of Health Value Innovation (CHVI) — thought leader on value-based benefit design And many more renowned thought leaders and senior industry executives.

Key Quotes

"It is no longer simply about drug cost but total cost of care to demonstrate a product's value. Pharma is beginning to understand that." Dr. Marcus Wilson, vice president, WellPoint, HealthCore Inc

"If drugmakers haven't got the relevant health economic data together to support the price of a new drug then it's never going to float." Michael Morgan-Curran, director, mHealth Diabetes, GSMA; director/owner, MM-C Innovative Solutions

"Each payer is different and to create and maintain long term mutually beneficial relationships, pharmaceutical companies must understand a payer's environment, the way they work, their needs and drivers." Elliot Rosen, managing director, Accession Healthcare Consultancy

Executive Summary Introduction > Payers: who's who> US payers> European payers> Payer organisations in the UK ( England and Wales)> Scotland> France> GermanyChanging landscape > Rapid growth of high-priced biologics and specialty drugs> A shift from volume-driven contracts to value-based pricing> Patient non-adherence: a costly problem> Payers demand real-world data> Health economic data: is it good enough for payers?> Patient powerThe drug manufacturer conundrum The changing drug manufacturer-payer relationship What payers want > Measuring health outcomes> QALY and ICER> Comparative effectiveness research, pragmatic clinical trials and adoptive licensing agreements> Improving market access via adaptive licensing> Market access agreements: health outcomes and risk-sharing schemes> Innovative US drug manufacturer-payer alliances and partnerships> Building better relationshipsThe new drugmaker-payer relationship > HTA and value-based pricing are here to stay> CER is becoming the new normal> Quality of economic modelling and health outcomes data is vital> Cost of a drug vs cost of care> Best-price frameworks> When to approach payers> Moving From transaction to collaboration builds trust> Sharing and exchanging patient dataOpening new communication channels is essential > Create an environment of accountabilityMoving forward together Conclusions

To order this report: Drug_and_Medication Industry: Pharma and Payers – Building Better Relationships

__________________________Contact Nicolas: nicolasbombourg@reportlinker.comUS: (805)-652-2626Intl: +1 805-652-2626

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,251.38 +94.53 0.55%
S&P 500 2,009.19 +7.62 0.38%
NASDAQ 4,589.7910 +27.6020 0.60%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs